LivaNova PLC (LIVN) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of LivaNova PLC $75.26, price $77.16, upside -2.5%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch LivaNova PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $33.85 – $92.68 · fair‑value band $44.91 – $129.17 · the $77.16 price screens above the $75.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow LivaNova in your weekly email
Every Wednesday you see whether LivaNova is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.
Show more
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Stock analysis
LivaNova PLC (LIVN) currently trades at $77.16, while our model-based Fair Value estimate is $75.26, implying the stock looks roughly 2.5% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $74.97 per share, and 3 of the 13 models we run sit above the $77.16 price.
Bear case: the Asset-Based group reads lowest at $14.64, and 10 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: $44.91 (bear) to $129.17 (bull), the price of $77.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
LivaNova PLC reported revenue of $1.4B in FY2025 versus $1.0B in FY2021, a compound +7.6%/yr. Reported net income was −$243M in FY2025.
Key figures
Market cap $4.2B · P/E ratio 39.4 · P/S ratio 3.16 · EPS (TTM) $1.96 · Net margin −17.5% · Return on equity 9.5% · Return on assets (EBIT) 1.3% · Operating margin 14.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 10% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −2%, LIVN screens richer than that median.
Fair Value models
Bear $44.91Fair Value $75.26Bull $129.17
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.43 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic). Over 10 years: +16.9% a year
Revenue growth 33 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.8% (2019) → 10.3% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.5% a year for the price and +4.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 364 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−3% · Above median
Profitability
Return on equity (TTM)10% · Above median
Return on assets5% · Top 25%
Net margin (TTM)7% · Above median
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth14% · Above median
Balance sheet
Debt / equity0.29× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "LivaNova PLC Fair Value". https://www.fairvalue-calculator.com/stock/LIVN
Frequently asked questions
Is LivaNova PLC (LIVN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $75.26 versus a price of $77.16, about −2% upside (fairly valued).
What is the fair value of LIVN?
Our model-based fair value for LivaNova PLC is $75.26 (as of Sep 24, 2026), built from audited fundamentals. The current price: $77.16.
What is the quality score of LIVN?
LivaNova PLC has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LivaNova PLC (LIVN)?
Our model-based price target is the fair value of $75.26 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario $44.91, optimistic scenario $129.17. It is a calculation from audited fundamentals, not an analyst target.
What is the LivaNova PLC stock forecast for 2026?
Our models put fair value at $75.26, about −2% upside versus a price of $77.16 (fairly valued). Cautious scenario $44.91, optimistic scenario $129.17. The calculation is refreshed regularly with new filings.
What is the revenue of LivaNova PLC (LIVN)?
LivaNova PLC reported trailing-twelve-month revenue of about $1.4B (latest available figure, as of Sep 24, 2026).
What growth is priced into LivaNova PLC (LIVN)?
For today's price to be fair in a discounted-cash-flow model, LivaNova PLC would have to grow free cash flow by +11.1 % per year for five years (discount rate 9.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of LIVN use?
Our models discount LivaNova PLC at 9.4 %: a base by market capitalisation (mid), damped by beta 0.86, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For LivaNova PLC that is +11.1 % per year a year over ten years, using the same discount rate (9.4 %) and the same formula as our fair value.
How much growth has LivaNova PLC (LIVN) delivered so far?
Over the past 5 years revenue at LivaNova PLC grew +8.2 % a year. The price currently implies +11.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of LivaNova PLC (LIVN) growing?
The median revenue growth in the sector is +4.1 % a year. That is the yardstick for the growth priced into LivaNova PLC (+11.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of LivaNova PLC (LIVN)?
The free-cash-flow yield on the price is 4.12 %: that much free cash flow LivaNova PLC produces per unit of market value. When it exceeds the discount rate of our models (9.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of LivaNova PLC (LIVN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LivaNova PLC it is $75.26 per share (as of Sep 24, 2026), against a price of $77.16. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is LivaNova PLC stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LIVN trades above its calculated fair value: price $77.16, fair value $75.26, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LIVN?
No. The price is what the market pays today ($77.16); the fair value is what the company's own numbers justify ($75.26). For LivaNova PLC the two are $1.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is LivaNova PLC worth?
The market values LivaNova PLC at about $4.2B (market capitalisation, as of Sep 24, 2026). Per share that is $77.16; our models calculate a fair value of $75.26 per share.
What do the bullish and bearish scenarios say about LIVN?
Our models span a range for LivaNova PLC: cautious scenario $44.91, base $75.26, optimistic $129.17 per share (as of Sep 24, 2026, price $77.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LIVN?
LivaNova PLC trades at a price-to-earnings ratio of 39.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $75.26 is built from several models across several years. Other multiples: PEG 0.9, P/B 3.5, P/S 2.9, EV/EBITDA 14.9.
What is the PEG ratio of LIVN?
The PEG ratio of LivaNova PLC is 0.93 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of LivaNova PLC (LIVN)?
Balance-sheet figures for LivaNova PLC (as of Sep 24, 2026): return on equity 9.5%, debt of 0.29 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is LIVN from its 52-week high?
LivaNova PLC trades at $77.16, about 10% below its 52-week high of $85.33 and 56% above the low of $49.57 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $75.26 is for.
Which stocks are comparable to LivaNova PLC?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LivaNova PLC stock attractive at the current price?
The data as of Sep 24, 2026: price $77.16, calculated fair value $75.26 (−2%), Quality Score 55/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LIVN calculated?
We run LivaNova PLC through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $75.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. LivaNova PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LivaNova PLC (LIVN)?
The closing price on Sep 23, 2026 was $77.16. Our model-based fair value is $75.26, about −2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LivaNova PLC right now?
The model range is unusually wide ($44.91 to $129.17). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of LivaNova PLC
How large is the market capitalisation of LivaNova PLC (LIVN)?
The market capitalisation of LivaNova PLC is $4.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LivaNova PLC (LIVN)?
The price-to-sales ratio of LivaNova PLC is 3.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LivaNova PLC (LIVN)?
Earnings per share at LivaNova PLC are $1.96 (price ÷ EPS = P/E 39.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of LivaNova PLC (LIVN)?
The net margin of LivaNova PLC is −17.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LivaNova PLC (LIVN)?
The return on equity (ROE) of LivaNova PLC is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LivaNova PLC (LIVN)?
On an EBIT basis the return on assets of LivaNova PLC is 1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LivaNova PLC (LIVN)?
The operating margin of LivaNova PLC is 14.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LivaNova PLC (LIVN)?
Revenue at LivaNova PLC is growing +14.3% versus a year earlier (3y avg +10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LivaNova PLC (LIVN)?
Earnings per share at LivaNova PLC are growing −45.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does LivaNova PLC (LIVN) hold?
LivaNova PLC holds more cash than debt, $162M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch LivaNova PLC in the live analysis
One click puts LivaNova PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026